Evgen Pharma in talks about funding for Covid-19 clinical trial
AIM-listed Evgen Pharma said on Friday that it is in talks with a potential source of funds that would help pay for a clinical trial in Covid-19 patients, in which it would provide support with its lead product, SFX-01.
FTSE AIM All-Share
755.28
17:14 26/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
0.10%
22.78
Theracryf
0.80p
16:49 26/04/24
0.00%
0.00p
The lead product from Evgen, which is a clinical stage drug development company focusing on the treatment of cancer and neurological conditions, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
The statement was made in response to a rise in the share price in recent days.
"A further announcement will be made if these discussions are successful," it said.
At 1305 BST, the shares were up 27% at 14.48p.